Speak directly to the analyst to clarify any post sales queries you may have.
Plasma protein therapeutics consist of medications derived from human plasma, the liquid component of the blood that contains essential proteins responsible for various functions necessary to human health. These therapeutics include an array of highly specialized treatments tailored to address a variety of medical conditions resulting from the absence or malfunctioning of specific plasma proteins. The market for plasma protein therapeutics includes developing, producing, and distributing these proteins for clinical use. Increased prevalence of autoimmune and neurological diseases, along with the increasing need for regular infusions or injections throughout the life of the patient, contribute to the growth of the plasma protein therapeutics market. Surging access and affordability of plasma protein therapies for patients also fuel the market development. The adverse effects of plasma protein therapeutics and strict regulations about handling plasma protein are restricting market growth. Increasing research and development activity related to the plasma protein presents a potential opportunity for growth in the plasma protein therapeutics market. The development of an efficient protein plasma extraction/manufacturing process is expected to create growth in the market.
Regional Insights
The plasma protein therapeutics market in the Americas is highly developing, with the United States being one of the major global markets, driven by advanced healthcare infrastructure, high patient awareness levels, and the presence of key industry players. The regulatory environment fostered by the FDA ensures stringent quality and safety standards. In South America, Brazil and Argentina are emerging as key markets for plasma protein therapeutics due to growing healthcare expenditures and awareness about plasma-derived therapies. The Asia-Pacific (APAC) region presents a growth opportunity for the plasma protein therapeutics market, attributed to rising healthcare awareness, increasing disposable incomes, and a growing aging population. China and Japan are significant markets in this region, with China investing heavily in plasma collection and fractionation capabilities. Europe has well-established healthcare systems, high-quality standards, and favorable reimbursement policies. The need for immunoglobulins remains robust, and European countries are significant exporters of plasma products. The Gulf Cooperation Council (GCC) countries demonstrate a rising need for plasma protein therapeutics due to economic prosperity and increased healthcare spending. Conversely, Africa faces considerable hurdles in healthcare infrastructure and treatment access, although the interest in plasma-derived medicinal products is growing.Product: Rising usage of C1-esterase inhibitors to control and prevent the swelling attacks associated with HAE
Albumin, a protein synthesized by the liver, is responsible for maintaining oncotic blood pressure and transporting hormones, enzymes, and drugs. In therapeutics, albumins are often used as volume expanders in cases of shock or burns and to treat hypoalbuminemia due to liver failure, nephrotic syndrome, or gastrointestinal protein loss. C1-esterase inhibitors are proteins that regulate the complement system, which is part of the body's immune response. They are primarily used to treat hereditary angioedema (HAE), a rare genetic condition that causes swelling in various parts of the body. Coagulation factors are essential proteins in the blood clotting process. Therapeutic coagulation factors prevent and control bleeding in individuals with hemophilia A and B, which are genetic disorders that impair blood clotting. Treatments involve replacing defective or missing clotting factors, which can be administered prophylactically to prevent bleeding episodes or on-demand to manage acute bleeding. Hyperimmune globulins are plasma-derived immunoglobulins with high concentrations of antibodies targeting specific pathogens or toxins. They are used to prevent or treat diseases such as hepatitis B, rabies, tetanus, and certain types of infections in immunocompromised patients. Immunoglobulins (Ig), also known as antibodies, are used in treating a wide array of autoimmune and inflammatory diseases, primary and secondary immunodeficiencies, and certain infections. Intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) are the two main forms offered, with the choice largely depending on patient preference, tolerability, and vein accessibility. Specific clinical needs lead to the choice among plasma protein products. Albumins and coagulation factors provide critical volume and clotting functions, respectively, often with high-urgency use cases like trauma and surgery and bleeding control for the latter. C1-esterase inhibitors and hyperimmune globulins offer more targeted interventions, focusing on genetic and infectious diseases. Immunoglobulins have the broadest application range, treating various autoimmune and immunodeficiency-related conditions. The manufacturing landscape is dominated by a few key players who robustly respond to medical needs, emphasized by recent advancements such as gene therapies and expanded indications for existing treatments.Application: Growing application of plasma protein therapeutics in the secondary immunodeficiency due to prevalence of cancer and autoimmune diseases
Hereditary angioedema is a rare genetic disorder indicated by sudden, severe, and unpredictable swelling in various parts of the body. Treatment for HAE involves C1 esterase inhibitor (C1-INH) concentrates and, more recently, recombinant C1-INH therapies and kallikrein inhibitors as on-demand treatment and prevention. The need for these therapies is high, given the life-threatening nature of HAE attacks. Idiopathic thrombocytopenic purpura is an autoimmune disease that results in a low platelet count, leading to easy bruising and bleeding. Intravenous immunoglobulin (IVIG) is generally used to treat ITP, as it can quickly elevate platelet counts. Primary Immunodeficiency Disorders (PID) represent a group of over 300 disorders where part of the body's immune system is missing or functions improperly. Patients typically require lifelong therapy, often with immunoglobulin (Ig) replacement. Secondary Immunodeficiency (SID) arises when an external source such as infection, chemotherapy, or another disease impairs the immune system. The therapeutic needs across these four application segments vary significantly, with demand being shaped by both the acuteness and the chronic nature of each condition. While HAE and ITP typically require rapid response treatments, PID and SID require longer-term management strategies.Industry Insights
- Market Dynamics
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
- FPNV Positioning Matrix
- Market Share Analysis
- Strategy Analysis and Recommendations
Recent Developments
GC Biopharma's groundbreaking for the plasma fractionation plant in Indonesia
GC Biopharma Corp inaugurated a plasma fractionation facility at the Jababeka Industrial Estate in Indonesia. This initiative builds on GC Biopharma's distinguished global plasma product plant construction record, with successful deployments in Thailand, China, and Canada.PlasmaGen Biosciences Opens New, State-of-the-Art Manufacturing Facility for Blood Plasma Products in Kolar, Bengaluru
PlasmaGen Biosciences inaugurated its advanced blood plasma-derived therapeutics manufacturing plant in Kolar, Bengaluru. The facility, which spans 8 acres, incorporates sophisticated independent but interlinked blocks designed for efficient operational workflows.Takeda to build USD 770 million plasma-derived therapy plant in Japan
Takeda Pharmaceutical Company Limited announced a significant investment in the Japanese healthcare infrastructure by constructing a state-of-the-art USD 770 million facility in Osaka. This venture, which is Takeda's most substantial manufacturing capacity expansion in Japan, is set to be the plasma protein therapeutic (PDT) plant in the country.Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Plasma Protein Therapeutics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.Key Company Profiles
The report delves into recent significant developments in the Plasma Protein Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Access Biologicals LLC, ADMA Biologics, Inc., AmerisourceBergen Corporation, Baxter International Inc., Bio Products Laboratory Ltd., Bruker Corporation, China Biologic Products Holdings, Inc., CSL Limited, DiaPharma, Emergent BioSolutions, FFF Enterprises, Inc., GC Biopharma corp, Grifols, S.A., Hemarus Therapeutics Limited, KalVista Pharmaceuticals, Kamada Ltd., Kedrion S.p.A., Laboratory Corporation of America Holdings, LFB SA, Octapharma AG, Plasma Technologies, LLC, PlasmaGen BioSciences Pvt. Ltd., Reliance Industries Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific, Inc..This research report offers invaluable insights into various crucial aspects of the Plasma Protein Therapeutics Market:
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
Companies Mentioned
- Access Biologicals LLC
- ADMA Biologics, Inc.
- AmerisourceBergen Corporation
- Baxter International Inc.
- Bio Products Laboratory Ltd.
- Bruker Corporation
- China Biologic Products Holdings, Inc.
- CSL Limited
- DiaPharma
- Emergent BioSolutions
- FFF Enterprises, Inc.
- GC Biopharma corp
- Grifols, S.A.
- Hemarus Therapeutics Limited
- KalVista Pharmaceuticals
- Kamada Ltd.
- Kedrion S.p.A.
- Laboratory Corporation of America Holdings
- LFB SA
- Octapharma AG
- Plasma Technologies, LLC
- PlasmaGen BioSciences Pvt. Ltd.
- Reliance Industries Limited
- Takeda Pharmaceutical Company Limited
- Thermo Fisher Scientific, Inc.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 185 |
Published | May 2024 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 36.19 Billion |
Forecasted Market Value ( USD | $ 69.18 Billion |
Compound Annual Growth Rate | 11.3% |
Regions Covered | Global |
No. of Companies Mentioned | 25 |